Via Nova Therapeutics
Oakland
About Via Nova Therapeutics
Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses, and rhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The company targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $25.0M
- Last round: Series Unknown (Sep 2021)
- Website: vianovatx.com
- Phone: 510-227-2102
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/via-nova-therapeutics-7845 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.